Targeting FOXO kills two birds with one stone.
PTEN deficiency activates Akt signaling and results in a variety of human malignancies. Encouragingly, recent studies demonstrate that small molecules can regulate FOXO1a, an Akt target, to suppress tumor growth, and FOXO1a is therefore a promising anticancer drug target.
Wang
Wenge
W
Howard Hughes Medical Institute, Department of Medicine, University of Pennsylvania School of Medicine, Philadelphia 19104, USA.
El-Deiry
Wafik S
WS
D000970:Antineoplastic Agents / Q000494:pharmacology*; D004268:DNA-Binding Proteins / Q000494:pharmacology*; D000071161:Forkhead Box Protein O1; D051858:Forkhead Transcription Factors; D006801:Humans; D017346:Protein Serine-Threonine Kinases / Q000187:drug effects / Q000502:physiology; D011518:Proto-Oncogene Proteins / Q000187:drug effects / Q000502:physiology; D051057:Proto-Oncogene Proteins c-akt; D015398:Signal Transduction / Q000187:drug effects; D014157:Transcription Factors / Q000494:pharmacology*; D025521:Tumor Suppressor Proteins / Q000502:physiology
D000970:Antineoplastic Agents; D004268:DNA-Binding Proteins; C085126:FOXO1 protein, human; D000071161:Forkhead Box Protein O1; D051858:Forkhead Transcription Factors; D011518:Proto-Oncogene Proteins; D014157:Transcription Factors; D025521:Tumor Suppressor Proteins; C494918:AKT1 protein, human; D017346:Protein Serine-Threonine Kinases; D051057:Proto-Oncogene Proteins c-akt